Sunshine Biopharma Files 8-K on Security Holder Vote

TL;DR

**Sunshine Biopharma just filed an 8-K about a recent shareholder vote, so keep an eye out for details on what was approved or rejected!**

AI Summary

Sunshine Biopharma, Inc. filed an 8-K on February 16, 2024, reporting on matters submitted to a vote of security holders on February 13, 2024. The filing indicates that the company, incorporated in Colorado with IRS Employer ID No. 20-5566275, is located at 6500 Trans-Canada Highway, 4th Floor, Pointe-Claire, Quebec, Canada. This 8-K is a current report under Section 13 or 15(d) of the Securities Exchange Act of 1934.

Why It Matters

This filing signals that Sunshine Biopharma's shareholders have voted on specific matters, which could impact the company's future direction, governance, or capital structure.

Risk Assessment

Risk Level: low — This 8-K is a procedural filing about a shareholder vote, not an event that inherently carries high risk.

Key Players & Entities

• Sunshine Biopharma, Inc. (company) — Registrant
• February 13, 2024 (date) — Date of earliest event reported
• February 16, 2024 (date) — Filing date
• Colorado (company) — State of incorporation
• 20-5566275 (dollar_amount) — IRS Employer ID No.
• 6500 Trans-Canada Highway (company) — Business address

FAQ

Key Financial Figures

• $0.001 — ch Registered Common Stock, par value $0.001 SBFM The Nasdaq Stock Market LLC

Filing Documents

• sunshine_8k.htm (8-K) — 28KB
• 0001683168-24-001049.txt ( ) — 241KB
• sbfm-20240213.xsd (EX-101.SCH) — 3KB
• sbfm-20240213_def.xml (EX-101.DEF) — 26KB
• sbfm-20240213_lab.xml (EX-101.LAB) — 36KB
• sbfm-20240213_pre.xml (EX-101.PRE) — 25KB
• sunshine_8k_htm.xml (XML) — 5KB

07 Submission of Matters to a Vote of

Item 5.07 Submission of Matters to a Vote of Security Holders. On February 13, 2024, Dr. Steve Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma, Inc. (the "Company"), approved by written consent: to give full effect to alternative cashless exercises pursuant to Section 2.3 of the Series A Warrants (the "Series A Warrants") issued pursuant to the underwriting agreement (the "Underwriting Agreement"), dated February 13, 2024, between the Company and Aegis Capital Corp., as underwriter; to any adjustment to the exercise price or number of shares of common stock underlying the Series A Warrants or the Series B Warrants (issued pursuant to the Underwriting Agreement) (the "Series B Warrants," and collectively with the Series A Warrants, the "Warrants") in the event of a Share Combination Event (as defined in the Series A Warrants and Series B Warrants) in Section 3.7 of the Series A Warrants and 3.8 of the Series B Warrants; to the voluntary adjustment, from time to time, of the exercise price of any and all currently outstanding Warrants pursuant to Section 3.8 of the Series A Warrants and 3.9 of the Series B Warrants; to render inapplicable clause (i) of the definition of the Floor Price (as defined in the Series B Warrant) in Section 3.2 of the Series B Warrants; and to give full effect to the adjustment in the exercise price and number of Warrant Shares (as defined in the Series B Warrants) following a Dilutive Issuance (as defined in the Series B Warrants) pursuant to Section 3.2 of the Series B Warrants. The consent will be effective 20 days after the definitive information statement relating to such consent is mailed to shareholders. As of February 13, 2024, Dr. Slilaty, who is the Company's chief executive officer, held 58.3% of the total voting power of the Company's stockholders. 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 16, 2024 SUNSHINE BIOPHARMA, INC. By: /s/ Dr. Steve N. Slilaty Name: Dr. Steve N. Slilaty Title: Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR